Immatics N.V.
The provided search snippets contain instructions for using Microsoft Word and are not relevant to Immatics N.V., a biotech company; therefore, no valid company data can be extracted.
Classification
Profile
Funding
Funding details not yet available.
Immatics develops and commercializes T-cell receptor (TCR) therapies to target solid tumors that are difficult to treat with current cell therapies, leveraging its proprietary ImmTAC platform.
B2B (pharmaceutical and biotechnology companies) for licensing and partnerships; potentially B2B/B2G for clinical trials and healthcare providers.
licensing, partnerships, grants, and commercial sales of therapeutic candidates.
channel partners, strategic alliances, direct sales for licensing.
Major pharmaceutical companies (e.g., AstraZeneca, Boehringer Ingelheim, Sanofi) for co-development and commercialization.
high R&D costs for clinical trials, regulatory compliance, and IP maintenance.
proprietary ImmTAC platform technology, extensive TCR database, patent portfolio, specialized biotech talent.
R&D, drug discovery, clinical trials, regulatory affairs, technology platform development.
sales-led for partnerships, community/research engagement for scientific validation.
Competes with other T-cell therapies like CAR-T (e.g., Kite Pharma/Gilead, Novartis) and other TCR therapy developers (e.g., Allogene, Immatics' peers in solid tumor cell therapy). Differentiated by targeting intracellular antigens via MHC restriction.
Limited treatment options for solid tumors using cell therapy, high cost and complexity of current CAR-T therapies, need for broader target range.
- Accelerate Bispecific Commercialization - prioritize IND filing for the most advanced bispecific candidate to capture the “off-the-shelf”
The analysis draws on the company’s 2024 financial release (revenue $161.9 M) and public collaboration announcements (BMS, Moderna, Amgen) - · Competitive insights are cross-checked against industry reports (2025-2026) from Frost & Sullivan and peer-reviewed publications on TCR ther · Social-media pain-point data were harvested from Twitter API and
No investors recorded yet.